The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.

Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.

Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.

A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).

A method is provided for reducing a risk that a subject will experience a medically-related adverse event associated with inappropriate consumption of alcohol concurrent with the taking of a nonbenzodiazepine benzodiazepine receptor agonist (NBBRA). In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more NBBRAs, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the NBBRA in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing the risk of the subject experiencing an alcohol-induced medically-related adverse event. Also disclosed are the combination products that include the effective amount of one or more NBBRAs and the effective amount of one or more ALDIs.

A method is provided for reducing a risk that a subject will experience a medically-related adverse event associated with inappropriate consumption of alcohol concurrent with the taking of a nonbenzodiazepine benzodiazepine receptor agonist (NBBRA). In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more NBBRAs, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the NBBRA in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing the risk of the subject experiencing an alcohol-induced medically-related adverse event. Also disclosed are the combination products that include the effective amount of one or more NBBRAs and the effective amount of one or more ALDIs.

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Provided are a compound represented by formula (I) or a salt thereof, a nerve growth promoter containing the compound or a salt thereof as an active ingredient, a pharmaceutical composition containing the compound or a salt thereof, a therapeutic agent for neurodegenerative diseases containing the compound or a salt thereof as an active ingredient, a therapeutic agent for amyotrophic lateral sclerosis containing the compound or a salt thereof as an active ingredient, a therapeutic agent for pain containing the compound or a salt thereof as an active ingredient, and a therapeutic agent for lower urinary tract dysfunction containing the compound or a salt thereof as an active ingredient.